United States & Novo Nordisk
18 shared events · Importance 3 · Last updated Jul 02, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
United States: The studies discussed involve patients and practices within the United States>>> and address a significant health concern for American women.
Novo Nordisk: Novo Nordisk>>> produces GLP-1 drugs like Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 45 articles
Tech
United States: The study analyzed data from US adults, and the findings could have public health implications for the United States regarding violence prevention.
Novo Nordisk: Novo Nordisk manufactures Semaglutide and Semaglutide, and the study's findings could potentially broaden the market and perceived benefits of its GLP-1 medications.
Jun 17, 2026 · 6 articles
Business
Novo Nordisk: Novo Nordisk announced significant job cuts and a revised profit outlook due to increased competition and slowing sales of its key weight-loss and diabetes drugs. The company aims to simplify its structure and reallocate resources for future growth.
Sep 10, 2025 · 6 articles
Business
Novo Nordisk: Novo Nordisk partnered with Costco to expand access and sales of its GLP-1 medications, Semaglutide and Semaglutide, at a standardized discounted price, combating competition from compounding pharmacies.
Oct 03, 2025 · 8 articles
Regulatory
Novo Nordisk: Novo Nordisk agreed to lower prices for its obesity drug Wegovy, making it more accessible to United States — Medicare and United States — Medicaid recipients and those paying directly. The company's spokesperson declined to provide specific details on pricing changes.
Nov 06, 2025 · 6 articles
Tech
Novo Nordisk: Novo Nordisk produces Semaglutide and Semaglutide, which are GLP-1 agonist drugs. The research indicates that patients regain weight quickly after discontinuing these medications, potentially impacting long-term sales and cost-effectiveness assessments by health systems.
Jan 08, 2026 · 6 articles
Business
Novo Nordisk: Novo Nordisk launched its Wegovy pill in the United States, aiming to attract new consumers and regain market share in the competitive weight-loss drug market. This launch is expected to boost its fortunes after previous profit warnings and sliding shares.
Jan 05, 2026 · 7 articles
Regulatory
Novo Nordisk: Novo Nordisk received United States — Food and Drug Administration approval for its Wegovy pill, gaining an edge in the obesity treatment market over Eli Lilly and Company. The company expects the pill to be available within weeks, with a starting dose of $149 per month.
Dec 22, 2025 · 23 articles
NEWSDESK
Explore this relationship live
Track how United States and Novo Nordisk interact across events, view sentiment trends, and discover connected entities.
Open Dashboard